Cargando…
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673712/ https://www.ncbi.nlm.nih.gov/pubmed/37945748 http://dx.doi.org/10.1038/s41388-023-02839-8 |
_version_ | 1785140679988477952 |
---|---|
author | Callens, Celine Rodrigues, Manuel Briaux, Adrien Frouin, Eleonore Eeckhoutte, Alexandre Pujade-Lauraine, Eric Renault, Victor Stoppa-Lyonnet, Dominique Bieche, Ivan Bataillon, Guillaume Karayan-Tapon, Lucie Rochelle, Tristan Heitz, Florian Cecere, Sabrina Chiara Pérez, Maria Jesús Rubio Grimm, Christoph Nøttrup, Trine Jakobi Colombo, Nicoletta Vergote, Ignace Yonemori, Kan Ray-Coquard, Isabelle Stern, Marc-Henri Popova, Tatiana |
author_facet | Callens, Celine Rodrigues, Manuel Briaux, Adrien Frouin, Eleonore Eeckhoutte, Alexandre Pujade-Lauraine, Eric Renault, Victor Stoppa-Lyonnet, Dominique Bieche, Ivan Bataillon, Guillaume Karayan-Tapon, Lucie Rochelle, Tristan Heitz, Florian Cecere, Sabrina Chiara Pérez, Maria Jesús Rubio Grimm, Christoph Nøttrup, Trine Jakobi Colombo, Nicoletta Vergote, Ignace Yonemori, Kan Ray-Coquard, Isabelle Stern, Marc-Henri Popova, Tatiana |
author_sort | Callens, Celine |
collection | PubMed |
description | The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the PAOLA-1/ENGOT-ov25 trial (NCT02477644), where HRD was detected by MyChoice CDx PLUS test. The academic shallowHRDv2 test was developed based on shallow whole-genome sequencing as an alternative to MyChoice. Analytical and clinical validities of shallowHRDv2 as compared to MyChoice on 449 PAOLA-1 tumor samples are presented. The overall agreement between shallowHRDv2 and MyChoice was 94% (369/394). Less non-contributive tests were observed with shallowHRDv2 (15/449; 3%) than with MyChoice (51/449; 11%). Patients with HRD tumors according to shallowHRDv2 (including BRCAmut) showed a significantly prolonged PFS with bev+ola versus bev (median PFS: 65.7 versus 20.3 months, hazard ratio (HR): 0.36 [95% CI: 0.24–0.53]). This benefit was significant also for BRCA1/2 wild-type tumors (40.8 versus 19.5 months, HR: 0.45 [95% CI: 0.26–0.76]). ShallowHRDv2 is a performant, clinically validated, and cost-effective test for HRD detection. |
format | Online Article Text |
id | pubmed-10673712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106737122023-11-09 Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial Callens, Celine Rodrigues, Manuel Briaux, Adrien Frouin, Eleonore Eeckhoutte, Alexandre Pujade-Lauraine, Eric Renault, Victor Stoppa-Lyonnet, Dominique Bieche, Ivan Bataillon, Guillaume Karayan-Tapon, Lucie Rochelle, Tristan Heitz, Florian Cecere, Sabrina Chiara Pérez, Maria Jesús Rubio Grimm, Christoph Nøttrup, Trine Jakobi Colombo, Nicoletta Vergote, Ignace Yonemori, Kan Ray-Coquard, Isabelle Stern, Marc-Henri Popova, Tatiana Oncogene Article The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the PAOLA-1/ENGOT-ov25 trial (NCT02477644), where HRD was detected by MyChoice CDx PLUS test. The academic shallowHRDv2 test was developed based on shallow whole-genome sequencing as an alternative to MyChoice. Analytical and clinical validities of shallowHRDv2 as compared to MyChoice on 449 PAOLA-1 tumor samples are presented. The overall agreement between shallowHRDv2 and MyChoice was 94% (369/394). Less non-contributive tests were observed with shallowHRDv2 (15/449; 3%) than with MyChoice (51/449; 11%). Patients with HRD tumors according to shallowHRDv2 (including BRCAmut) showed a significantly prolonged PFS with bev+ola versus bev (median PFS: 65.7 versus 20.3 months, hazard ratio (HR): 0.36 [95% CI: 0.24–0.53]). This benefit was significant also for BRCA1/2 wild-type tumors (40.8 versus 19.5 months, HR: 0.45 [95% CI: 0.26–0.76]). ShallowHRDv2 is a performant, clinically validated, and cost-effective test for HRD detection. Nature Publishing Group UK 2023-11-09 2023 /pmc/articles/PMC10673712/ /pubmed/37945748 http://dx.doi.org/10.1038/s41388-023-02839-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Callens, Celine Rodrigues, Manuel Briaux, Adrien Frouin, Eleonore Eeckhoutte, Alexandre Pujade-Lauraine, Eric Renault, Victor Stoppa-Lyonnet, Dominique Bieche, Ivan Bataillon, Guillaume Karayan-Tapon, Lucie Rochelle, Tristan Heitz, Florian Cecere, Sabrina Chiara Pérez, Maria Jesús Rubio Grimm, Christoph Nøttrup, Trine Jakobi Colombo, Nicoletta Vergote, Ignace Yonemori, Kan Ray-Coquard, Isabelle Stern, Marc-Henri Popova, Tatiana Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title_full | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title_fullStr | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title_full_unstemmed | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title_short | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial |
title_sort | shallow whole genome sequencing approach to detect homologous recombination deficiency in the paola-1/engot-ov25 phase-iii trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673712/ https://www.ncbi.nlm.nih.gov/pubmed/37945748 http://dx.doi.org/10.1038/s41388-023-02839-8 |
work_keys_str_mv | AT callensceline shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT rodriguesmanuel shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT briauxadrien shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT frouineleonore shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT eeckhouttealexandre shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT pujadelauraineeric shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT renaultvictor shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT stoppalyonnetdominique shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT biecheivan shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT bataillonguillaume shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT karayantaponlucie shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT rochelletristan shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT heitzflorian shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT ceceresabrinachiara shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT perezmariajesusrubio shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT grimmchristoph shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT nøttruptrinejakobi shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT colombonicoletta shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT vergoteignace shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT yonemorikan shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT raycoquardisabelle shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT sternmarchenri shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial AT popovatatiana shallowwholegenomesequencingapproachtodetecthomologousrecombinationdeficiencyinthepaola1engotov25phaseiiitrial |